Moderna is actively looking to expand its
mRNA technology pipeline with the company announcing plans to seek approval for an mRNA flu shot. Renowned business television personality
Jim Cramer expressed potential growth expectations for Moderna’s stocks sighted on its strong R&D advancements. Significant financial support from CEPI for a pivotal Phase 3 Trial for Moderna’s
mRNA Pandemic Influenza Candidate is seen. Meanwhile, Moderna has increased 16.2% owing to its significant revision and uplift of its 2025 outlook in addition to cost-cutting measures. Its COVID vaccine has shown 53% effectiveness against adult hospitalization for the 2024-25 season. Amid these developments,
Bayer has filed lawsuits against Moderna and other key market players over COVID vaccine tech. Moderna has also scrapped its mRNA vaccine for congenital CMV after Phase III failure. In more upbeat news, the UK has opened a Moderna mRNA Vaccine Centre in Oxfordshire as the company expands its mRNA manufacturing in the US. Moderna's stocks have shown positive movements despite some fluctuations, and the company reiterated a target of up to 10% revenue growth in 2026.
Moderna MRNA News Analytics from Sat, 24 May 2025 07:00:00 GMT to Sat, 17 Jan 2026 11:18:10 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor -2
